Nasdaq ENLV
Investor Relations

Corporate profile

Enlivex is a clinical stage biopharmaceutical company developing Allocetra™, a universal, off-the-shelf cell therapy platform designed to restore the homeostatic state of macrophages, for the treatment of inflammatory diseases.

Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life-debilitating conditions.

Latest corporate presentationDOWNLOAD PDF
Nasdaq:ENLV
$1.20
6/27/2025 4:00 PMET
Change
▼ $-0.01(-0.83%)
Volume
66,559
Today's Open
$1.24
Previous Close
$1.21
Today's High
$1.24
Today's Low
$1.15
52 Week High
$1.76
52 Week Low
$0.81

Investment Highlights

Strong IP strategy for novel therapeutic modality.

Favorable safety profile demonstrated across several clinical studies.

Proposed MOA supported by clinical data.

Optimized manufacturing process yielding ready-to-use doses of off-the-shelf cell therapy platform.

Multi-billion-dollar market opportunity in several inflammatory disease markets with high unmet need.

Seasoned management team with a track record of successfully advancing therapies through regulatory approval.

Recent news releases

View all
10

June

2025

Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it will present a poster at the European Alliance of Associations for Rheumatology (EULAR) European C...
Read More
Jun 10, 2025
20

May

2025

Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy comp...
Read More
May 20, 2025
23

April

2025

Presentations to underscore AllocetraTM's novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced th...
Read More
Apr 23, 2025
View all